TORONTO, Oct. 9 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company focused on treatments and diagnostics for brain-wasting diseases, today announced that it will be presenting the results from its vaccine development program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, at the 132nd Annual Meeting of the American Neurological Association today in Washington, DC. The vaccine approach, also known as active immunization, is the second therapeutic approach for which proof-of-concept has been established by Amorfix for the treatment of ALS this year. In March, Amorfix established a passive immunization approach in the same mouse model of ALS by injecting monoclonal antibodies that target the misfolded superoxide dismutase 1 (SOD1) protein.
